Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015.
Some major news hit the IPO...read more
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated....read more
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday.
The South San Francisco, CA-based company now plans to raise $215 million by offering 13 million...read more
Updated Monday, 7/6. Following the long weekend, two Chinese IPOs, two biotechs, and a SPAC are currently scheduled to list in the US in the week ahead, inlcuding China’s largest LGBTQ dating app BlueCity (BLCT). More...read more
US IPO Weekly Recap: Preclinical biotech Nkarta pops 166% in a 5 IPO week
Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015. Some major news hit the IPO...read more
Preclinical oncology biotech Nkarta prices further upsized IPO at $18, above the upwardly revised range
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated....read more
Preclinical oncology biotech Nkarta raises proposed deal size by 43% ahead of $215 million IPO
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $215 million by offering 13 million...read more
US IPO Week Ahead: Third quarter kicks off with China’s largest gay dating app
Updated Monday, 7/6. Following the long weekend, two Chinese IPOs, two biotechs, and a SPAC are currently scheduled to list in the US in the week ahead, inlcuding China’s largest LGBTQ dating app BlueCity (BLCT). More...read more